News
NVO
128.39
+2.49%
3.13
TikTok to restrict weight loss drug promotion
Seeking Alpha · 5h ago
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF's top holdings include Eli Lilly, Novo Nordisk, and Johnson & Johnson. The fund has been in an uptrend since late last year and is currently trading at a level that presents a buying opportunity.
Seeking Alpha · 12h ago
Why Novo Nordisk Topped the Market Today
Danish pharmaceutical company Novo Nordisk bought 207,000 of its own shares last week. The company's shares rose more than 2% on the day. The Danish-based company is the company behind popular weight loss and diabetes drugs. It has a one-year stock buyback program.
The Motley Fool · 22h ago
Wall Street Lunch: Big Tech Bearishness?
UBS downgrades Apple, Amazon, Google, Meta, Microsoft and Nvidia. UBS sounded a warning on its list of Big 6 tech companies. Five risks to the $2 trillion private credit market. Verizon reported first-quarter earnings that topped estimates. Looking ahead to earnings and Verizon.
Seeking Alpha · 1d ago
Eli Lilly to acquire manufacturing facility from Nexus Pharma
Eli Lilly to acquire manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. Lilly expects production at the facility based in Pleasant Prairie, Wisconsin, to begin at the end of 2025. Soaring demand for GLP-1 agonists has led to constrained supply for drugmakers.
Reuters · 1d ago
Novo Nordisk Launches Massive Share Buyback
TipRanks · 1d ago
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Survey shows use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers’ spending habits. The drugs are popular in the food industry, particularly in the pharmaceuticals industry. Novo Nordisk and Eli Lilly and Co. Are two companies that make popular weight loss drugs.
Benzinga · 1d ago
Novo Nordisk Remains The Better Buy After A Moderate Pullback
Novo Nordisk A/S (NVO) continues to be rated as a Buy, with the stock already charting an impressive +16.1% rally over the past three months. The company is the US market leader in the obesity/diabetes market. The management recently announced multiple expansions in its manufacturing/fill finish capacities. With the ongoing shortages still implying immense consumer demand, we believe NVO remains a Buy at every dips.
Seeking Alpha · 1d ago
Weekly Report: what happened at NVO last week (0415-0419)?
Weekly Report · 1d ago
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 1d ago
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
There are a handful of appealing opportunities for long-term investment in the big pharma space. Vertex Pharmaceuticals' core strategy is to develop medicines to treat or cure rare diseases. Novo Nordisk makes its money by selling cardiometabolic drugs for some of the largest markets.
The Motley Fool · 3d ago
3 Relatively Safe Growth Stocks You Can Buy and Hold
The Motley Fool · 3d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 3d ago
Tech advances are catalyzing the Health Care sector with improved investor sentiment - SSGA
Healthcare Tech advances are catalyzing the Health Care sector with improved investor sentiment. The healthcare sector has seen higher earnings growth and help from advancing technologies. The sector is one of the few that has better long-term performance in Europe than in the US. European pharmaceutical and biotech companies have promising research and development productivity.
Seeking Alpha · 4d ago
What to Watch in the Week Ahead and on Monday, April 22
Tesla chief Elon Musk is expected to meet with India's Prime Minister Narendra Modi and announce plans to invest in and build a factory in the country. The week will see many major U.S companies release their financial report cards. Microsoft's revenue expected to have grown 15% as AI investments drive gains in the tech industry. A raft of economic data coming this week will be watched by the Federal Reserve policymakers.
Reuters · 4d ago
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. The healthcare industry can be a good place to invest for the long term. Three companies that trade at less than $500 each look like attractive long-term buys. Robotic-assisted surgery is the future of healthcare.
The Motley Fool · 4d ago
Peek Under The Hood: FVD Has 11% Upside
NASDAQ · 4d ago
ClearBridge International Growth ACWI Ex-US Strategy Q1 2024 Commentary
Seeking Alpha · 4d ago
U.S. Stocks Have Outperformed Europe for Years. Why That Could Change for a While.
J.P. Morgan is turning less bearish on Europe. European earnings are estimated to have shrunk by 11%, versus a 3% increase in the U.S. The Magnificent Seven tech stocks have shone in Europe, but earnings growth is slowing. The iShares Europe exchange-traded fund has underperformed the S&P 500.
Barron‘s · 4d ago
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Danish pharma giant Novo Nordisk A/S cleared to acquire Cardior Pharmaceuticals GmbH. Cardior is a biotech company focusing on heart diseases. The company's main development product is an active substance against cardiac insufficiency caused by heart attacks. The deal includes Cardior's lead compound for the treatment of heart failure.
Benzinga · 5d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.